A pharmacological differentiation between postjunctional (AT1A) and prejunctional (AT1B) angiotensin II receptors in the rabbit aorta.

Naunyn Schmiedebergs Arch Pharmacol

Faculdade de Medicina, Instituto de Farmacologia e Terapêutica, Alameda Hernani Monteiro, 4200-319 Porto, Portugal.

Published: October 2004

The effects of angiotensin II and angiotensin III were compared at prejunctional and postjunctional AT(1) receptors of the rabbit thoracic aorta. Furthermore, the influence of PD123319, losartan and eprosartan on these effects was also compared. To study prejunctional effects, the tissues were preincubated with ((3)H)-noradrenaline, superfused and electrically stimulated (1 Hz, 2 ms, 50 mA, 5 min). To study postjunctional effects, non-cumulative concentration-response curves were determined. Both angiotensin II and angiotensin III were more potent prejunctionally than postjunctionally. In the case of angiotensin II, the EC(50) was 12 times lower at the prejunctional than at the postjunctional level, while that of angiotensin III was 30 times lower prejunctionally. Furthermore, whereas angiotensin II was about 33 times more potent than angiotensin III postjunctionally, it was only 12 times more potent than angiotensin III prejunctionally. Eprosartan did not differentiate between prejunctional and postjunctional effects of both angiotensins. In contrast, PD123319 and losartan did differentiate; however, whereas PD123319 concentration-dependently antagonised the facilitation of tritium release caused by angiotensin II and angiotensin III and had no influence on the contraction of the aortic rings elicited by the peptides, losartan did the opposite: it concentration-dependently antagonised the contractions caused by the peptides on the aortic rings and exerted no influence on the facilitatory effect of angiotensin II and angiotensin III. These results show that prejunctional and postjunctional receptors for angiotensin II and angiotensin III are different and underline the hypothesis that postjunctional AT(1) receptors belong to the AT(1A) subtype, while prejunctional AT(1) receptors belong to the AT(1B) subtype.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00210-004-0977-7DOI Listing

Publication Analysis

Top Keywords

angiotensin iii
32
angiotensin angiotensin
20
angiotensin
16
prejunctional postjunctional
16
at1 receptors
12
receptors rabbit
8
iii
8
postjunctional at1
8
pd123319 losartan
8
postjunctional effects
8

Similar Publications

Aims: Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is unclear, thus Sac/Val according to ACEi/ARB status at baseline was assessed.

Methods And Results: This was a pre-specified analysis of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE-HF), a double-blind, randomized controlled trial of Sac/Val versus valsartan, categorizing patients according to baseline ACEi/ARB status. The primary endpoint was time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline through weeks 4 and 8.

View Article and Find Full Text PDF

Vasculo-Protective Effects of Standardized Black Chokeberry Extracts in Mice Aorta.

Int J Mol Sci

December 2024

Department III Functional Sciences-Pathophysiology, Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy of Timișoara, E. Murgu Sq., No. 2, 300041 Timisoara, Romania.

Black chokeberry ( Elliot) represents a rich source of dietary polyphenols and other bioactive phytochemicals with pleiotropic beneficial cardiovascular effects. The present study was aimed at evaluating the ex vivo effects of two black chokeberry extracts (BChEs), obtained from either dry (DryAr) or frozen (FrozAr) berries, on oxidative stress and vascular function in mice aortic rings after incubation with angiotensin 2 (Ang 2), lipopolysaccharide (LPS) and glucose (GLUC) in order to mimic renin-angiotensin system activation, inflammation and hyperglycemia.

View Article and Find Full Text PDF

Vaccination as a Promising Approach in Cardiovascular Risk Mitigation: Are We Ready to Embrace a Vaccine Strategy?

Biomolecules

December 2024

Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece.

Cardiovascular disease (CVD) remains a leading global health concern, with atherosclerosis being its principal cause. Standard CVD treatments primarily focus on mitigating cardiovascular (CV) risk factors through lifestyle changes and cholesterol-lowering therapies. As atherosclerosis is marked by chronic arterial inflammation, the innate and adaptive immune systems play vital roles in its progression, either exacerbating or alleviating disease development.

View Article and Find Full Text PDF
Article Synopsis
  • Recurrent hyperkalemia (HK) in patients with chronic kidney disease (CKD) is linked to significantly higher risks of all-cause mortality and cardiovascular (CV) issues compared to patients with normal potassium levels.
  • The study involved matching 6,337 patients with recurrent HK to those with normokalemia, adjusting for relevant factors, to ensure a fair comparison.
  • Findings indicated that recurrent HK is particularly detrimental, increasing risks for major adverse cardiovascular events (MACE+) and hospitalizations due to arrhythmias, affecting both the overall CKD population and those with co-occurring heart failure.
View Article and Find Full Text PDF

Introduction: Novel approaches to improve long-term outcomes in kidney transplant recipients are required. Here, we present the 5-year data from a multicenter, prospective, Phase 3b trial evaluating treatment outcomes with standard (STD) or low (LOW) dose prolonged-release tacrolimus (TAC) combined with ACEi/ARB or other antihypertensive therapy (OAHT) in Canadian kidney transplant recipients.

Methods: Adult de novo kidney transplant recipients were randomized 2 × 2 to STD or LOW dose TAC and ACEi/ARB or OAHT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!